David Ashley, MBBS, PhD

Professor of Neurosurgery
Rory David Deutsch Distinguished Professor of Neuro-Oncology
Professor of Medicine
Professor in Pathology
Professor in Pediatrics
Member of the Duke Cancer Institute
Campus mail 203 Research Dr Msrb1, Box 2600, Durham, NC 27710
Phone (919) 684-4164
Email address david.ashley@duke.edu

Dr. Ashley's primary research focus is laboratory based, investigating the role of immunotherapy as a novel approach to the treatment of tumors of the central nervous system (CNS). Since beginning his appointment at the faculty level at Duke in August of 1995 his activities have centered on two main areas of investigation. The first involves both in vivo and in vitro studies of the use of molecular therapeutics to target a CNS tumor associated antigen. The second area of interest comprises a detailed analysis of the role of TGF beta, a protein messenger produced by tumors of the CNS, both in the pathogenesis of disease and as a possible target for immunotherapy.

In addition to his laboratory role Dr. Ashley is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.

Education and Training

  • Ph.D., University of Melbourne (Australia), 1998
  • M.B.B.S., University of Melbourne (Australia), 1994
  • F.R.A.C.P., Royal Australasian College of Physicians (Australia), 1993

Grants

Publications

Sim, Hao-Wen, Kerrie L. McDonald, Zarnie Lwin, Elizabeth H. Barnes, Mark Rosenthal, Matthew C. Foote, Eng-Siew Koh, et al. “A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.” In Neuro Oncol, 23:1736–49, 2021. https://doi.org/10.1093/neuonc/noab111.

PMID
33984151
Full Text

Yu, Shengnan, Shiyou Wei, Milan Savani, Xiang Lin, Kuang Du, Ilgen Mender, Silvia Siteni, et al. “A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas.” Clin Cancer Res, September 30, 2021. https://doi.org/10.1158/1078-0432.CCR-21-0374.

PMID
34593527
Full Text

Singh, Kirit, Kristen A. Batich, Patrick Y. Wen, Aaron C. Tan, Stephen J. Bagley, Michael Lim, Michael Platten, et al. “Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, September 24, 2021. https://doi.org/10.1158/1078-0432.ccr-21-2681.

PMID
34561270
Full Text

Kang, Jennifer H., Christa B. Swisher, Evan D. Buckley, James E. Herndon, Eric S. Lipp, John P. Kirkpatrick, Annick Desjardins, et al. “Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.” Cns Oncol 10, no. 3 (September 1, 2021): CNS77. https://doi.org/10.2217/cns-2021-0009.

PMID
34545753
Full Text

Tan, Aaron C., Stephen J. Bagley, Patrick Y. Wen, Michael Lim, Michael Platten, Howard Colman, David M. Ashley, et al. “Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.” J Immunother Cancer 9, no. 7 (July 2021). https://doi.org/10.1136/jitc-2021-002459.

PMID
34215688
Full Text

Yang, Rui, Wenzhe Wang, Meichen Dong, Kristen Roso, Xuhui Bao, Christopher Pirozzi, Darell Bigner, et al. “BIOL-10. DISTRIBUTION AND VULNERABILITY OF TRANSCRIPTIONAL OUTPUTS ACROSS THE GENOME IN MYC-AMPLIFIED MEDULLOBLASTOMA CELLS.” In Neuro Oncology, 23:i5–i5. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab090.017.

Full Text

Thompson, Eric, Daniel Landi, Gerald Archer, Eric Lipp, Ashley Walter, Bridget Archambault, Bea Balajonda, et al. “EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL.” In Neuro Oncology, 23:i46–i46. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab090.187.

Full Text

Hanzlik, Emily, Bridget Archambault, Mays Dairi, Kristin Schroeder, Mallika Patel, Eric S. Lipp, Song Boucree, Katherine Peters, David Ashley, and Daniel Landi. “LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS.” In Neuro Oncology, 23:i32–33. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab090.132.

Full Text

Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Elizabeth S. Miller, Sarah Woodring, et al. “Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.” Neurooncol Pract 8, no. 3 (June 2021): 299–309. https://doi.org/10.1093/nop/npaa084.

PMID
34055377
Full Text

Srinivasan, Ethan S., Aaron C. Tan, Carey K. Anders, Ann Marie Pendergast, Dorothy A. Sipkins, David M. Ashley, Peter E. Fecci, and Mustafa Khasraw. “Salting the Soil: Targeting the Microenvironment of Brain Metastases.” Mol Cancer Ther 20, no. 3 (March 2021): 455–66. https://doi.org/10.1158/1535-7163.MCT-20-0579.

PMID
33402399
Full Text

Pages